Navigation Links
PharmAthene Reports Third Quarter 2011 Financial and Operating Results
Date:11/9/2011

ributable to common shareholders was $0.03 million, or $0.00 per share, compared to $4.3 million, or $0.14 per share, in the same period of 2010.  The year-over-year decrease in net loss includes the impact of the change in fair value of the Company's derivative instruments, which resulted in a non-cash decrease of expenses of $2.9 million for the three months ended September 30, 2011 compared to a non-cash decrease of expenses of $0.08 million for the same period in 2010. The decrease in fair value realized during the third quarter of 2011 was primarily the result of the decrease in PharmAthene's stock price from $2.94 per share on June 30, 2011 to $1.76 per share on September 30, 2011.

As of September 30, 2011, the Company had cash and cash equivalents, short-term investments, and net U.S. government accounts receivables and other receivables, including unbilled receivables, totaling approximately $16.9 million compared to $21.6 million at December 31, 2010.  The decrease at September 30, 2011 was primarily due to a combination of a loss from operations of $10.6 million, partially offset by proceeds from a registered direct public offering of common stock and warrants completed in June 2011, which raised net proceeds for the Company of $5.8 million, as well as a net reduction in receivables, prepaid expenses and other current assets and noncash expenses."During the quarter we made significant progress across our biodefense countermeasures programs, particularly in our development of our second generation anthrax vaccine, SparVax™," continued Mr. Richman.  "We recently completed the first 1,500 cGMP manufacturing production run as part of the development of a robust manufacturing process.  This is a significant achievement for our Company and enables us to potentially produce more than 150 million rPA vaccine equivalent doses of bulk drug substance at a 50 mcg dose.  We were also awarded a contract valued at $5.7 million
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. PharmAthene Progresses Second Generation rPA Anthrax Vaccine
2. PharmAthene Appoints Brian A. Markison to the Companys Board of Directors
3. PharmAthene Achieves Significant Progress in SparVax™ Anthrax Vaccine Program
4. Department of Defense Awards $5.7 Million Contract to PharmAthene for Nerve Agent Medical Countermeasure Program
5. PharmAthene Selected for Inclusion in the Russell Global Index and Russell 3000 Index
6. PharmAthene Achieves Anthrax Vaccine Program Milestone and Successfully Completes Technology Transfer
7. PharmAthene Completes $6.5 Million Registered Direct Offering
8. PharmAthene Reports First Quarter 2011 Financial and Operating Results
9. PharmAthene to Host Year-End 2010 Earnings Conference Call and Webcast on Monday, March 28, 2011
10. PharmAthene Strengthens Scientific Leadership and Program Management for Future Growth
11. PharmAthene Receives FDA Clearance to Reinitiate Clinical Testing of Valortim®
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... and NEW YORK , ... (NASDAQ:  PTBI), a biopharmaceutical company advancing protein biologic ... an overview of the Company,s 2014 achievements and ... below demonstrate the progress the Company has made ... corporate partnerships for its MuGard programs, the FDA ...
(Date:4/1/2015)... NEW YORK CITY and LONDON ... of market research reports and solutions, MarketResearch.com is pleased to ... will be a year of market growth and opportunity for ... stem cell company or cord blood bank, competing in the ... market conditions, predict industry trends, and act on market changes ...
(Date:4/1/2015)... OXFORD, England , April 1, 2015 /PRNewswire/ ... world-leading biotechnology company developing novel biological drugs to ... today pleased to announce the appointment of ... Coughlin will be responsible for providing medical and ... for the Company. Dr. Coughlin has ...
(Date:3/31/2015)... 2015 Eastern Kentucky University is ... bachelor’s of criminal justice degree programs by Nonprofitcollegesonline.com. ... inspiring ideas and high quality educational opportunities,” Editor ... University. We are confident that students will find ... is the site’s first “Students before Profits” list, ...
Breaking Biology Technology:PlasmaTech Biopharmaceuticals Provides Strategic Update for 2015 and Review of 2014 Acheivements 2PlasmaTech Biopharmaceuticals Provides Strategic Update for 2015 and Review of 2014 Acheivements 3PlasmaTech Biopharmaceuticals Provides Strategic Update for 2015 and Review of 2014 Acheivements 4PlasmaTech Biopharmaceuticals Provides Strategic Update for 2015 and Review of 2014 Acheivements 5PlasmaTech Biopharmaceuticals Provides Strategic Update for 2015 and Review of 2014 Acheivements 6MarketResearch.com: "Blockbuster" Year for Stem Cells Creates Market Opportunities, Says BioInformant Worldwide Report 2MarketResearch.com: "Blockbuster" Year for Stem Cells Creates Market Opportunities, Says BioInformant Worldwide Report 3MarketResearch.com: "Blockbuster" Year for Stem Cells Creates Market Opportunities, Says BioInformant Worldwide Report 4Immunocore Appoints Dr. Christina Coughlin as Chief Medical Officer 2Immunocore Appoints Dr. Christina Coughlin as Chief Medical Officer 3Immunocore Appoints Dr. Christina Coughlin as Chief Medical Officer 4EKU Ranked in Top 50 Among Online Criminal Justice Degrees 2
... Memory,Pharmaceuticals Corp. (Nasdaq: MEMY ) today ... the Company,s request for an,extension until December 3, ... market capitalization requirement of $35 million or the ... order to remain,listed. There can be no assurance ...
... Aortic ... Aneurysms, ... of Vascular Surgery was the first to implant, in,Phoenix, the Powerlink ... aortic aneurysms (AAA). The procedure was,performed at Arizona Heart Hospital by ...
... BOSTON, Oct. 31 PAREXEL International,Corporation (Nasdaq: ... at the,Oppenheimer 19th Annual Healthcare Conference in New ... Financial Officer will be making,a formal presentation on ... 3,2008., The presentation will be available under ...
Cached Biology Technology:Memory Pharmaceuticals Granted Extension to Comply with NASDAQ Listing Requirements 2Arizona Heart Institute First to Implant Powerlink XL in Phoenix, Arizona Since FDA Approval 2Arizona Heart Institute First to Implant Powerlink XL in Phoenix, Arizona Since FDA Approval 3PAREXEL International to Present at Oppenheimer 19th Annual Healthcare Conference 2
(Date:4/1/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... mobile commerce market, announces the second shipment of a ... early access pre-order customers. Feedback from ... including Walmart, Target, AT&T, Dunkin, Donuts, Stop & Shop ... all outlets and very easy to use. Several users ...
(Date:4/1/2015)... 2015   Medisafe ™, the leading global medication ... iOS and Android smartphones and tablets, ... the platform to allow patients to track and correlate ... time, patients will be able to visualize in real-time ... biometrics, such as glucose levels and blood pressure. ...
(Date:3/31/2015)... -- Elephant Talk Communications Corp. (NYSE MKT: ETAK) ("Elephant Talk" ... Network Architecture (ET Software DNA® 2.0) platforms and cyber ... million for the year ended December 31, 2014 as ... ended December 31, 2013. At the ... multi-year transition away from its legacy landline business to ...
Breaking Biology News(10 mins):NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 4Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6
... 2012 Childhood Obesity , a peer-reviewed journal from Mary ... dedicated to the role that schools can and should ... eating habits to help stem the tide of the ... provides comprehensive coverage of food policy, systems, and programs ...
... becomes extinct, other predatory species could soon follow, according to ... a University of Exeter team has now carried out the ... 2012) in the Royal Society journal Biology Letters , ... can indirectly cause another to become extinct. The University of ...
... Biofuels and Texas AgriLife Research, part of The Texas ... develop and commercialize cellulosic feedstocks for the production of ... diverse high biomass energy crop breeding program and BP ... companies growing commercial-scale biomass crops for liquid fuels. ...
Cached Biology News:School food -- on the front line in the fight against childhood obesity 2Study proves that 1 extinction leads to another 2BP Biofuels, Texas AgriLife Research sign agreement to advance biofuel feedstock development 2
QPRT Immunogen: QPRT (NP_055113, 198 a.a. ~ 298 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
...
Rabbit polyclonal to XTP4 ( Abpromise for all tested applications). entrezGeneID: 84299 SwissProtID: Q9BRT3...
...
Biology Products: